FiercePharmaAsia—Novartis' generics deal, Zolgensma decision delays; AZ's China performance

Asia Map
Novartis, Aurobindo, AstraZeneca and Takeda made our news this week. (Google)

Like many other pharma transactions, Sandoz's $1 billion U.S. oral solids and dermatology selloff to India's Aurobindo has been delayed by U.S. antitrust review. Novartis' Zolgensma faces delayed EU and Japan decisions, though CEO Vas Narasimhan said they had nothing to do with the recent data manipulation scandal. AstraZeneca dialed back its China growth to a mid-teens percentage increase as a bulk procurement scheme rolls out across the country. And more.

1. Novartis' Sandoz appears on the mend. But where is that Aurobindo U.S. generics deal?

Over a year has passed since the $1 billion acquisition deal for Novartis’ Sandoz U.S. oral solids and dermatology business, by India’s Aurobindo Pharma, was made public. And still, because of some “elements” the U.S. Federal Trade Commission (FTC) has requested, the two firms are expecting it’ll be months before they complete the transaction, Novartis CEO Vas Narasimhan said.

2. Novartis' Zolgensma faces EU, Japan delays after regulators raise 'manufacturing questions'

EU and Japanese regulators are raising some additional “manufacturing questions” that will delay Zolgensma’s approval in the territories into 2020. Narasimhan said the requests were not related to the company's recent data manipulation scandal. An inspection of Zolgensma’s manufacturing facility is scheduled for December, a company spokesperson said.

3. Has AstraZeneca finally arrived? Seems so, with oncology and China growth—at least for now

AstraZeneca previously said it had expected China growth to slow in the second half of the year. But in Q3, the country still turned up a whopping 40% increase at constant exchange rates. That’s because the national rollout of a bulk procurement program was slower than expected, CEO Pascal Soriot said. Moving forward, the company still expects growth in the mid-teens from China as it launches new products, such as blockbuster anti-EGFR lung cancer drug Tagrisso.

4. Takeda picks up Cour's celiac treatment, promising $420M in biobucks

Cour Pharma’s celiac disease candidate, CNP-101, previously showed it could cut levels of inflammation-promoting cytokines in a small phase 2a study. Now, Takeda has acquired an exclusive global license to the medicine with a payment of up to $420 million. Cour’s treatment is a nanoparticle loaded with gliadin—a component of gluten—to reprogram the immune system so it doesn’t attack the intestines when a person with celiac disease is exposed to gluten. 

5. Biogen's Spinraza is still churning—even after Novartis' rival Zolgensma launch

Samsung Bioepis’ biosimilars sales seemed stagnant in the EU in the third quarter. According to Biogen, the Samsung BioLogics joint venture partner, its three biosimilars—to Humira, Enbrel and Remicade—raked in $184 million in Q3, flat against Q2, and came 7.5% below the Street’s consensus. Enbrel copy Benepali, the company’s flagship product, dropped 6% over the same period last year to $116 million.

6. Shionogi, Janssen partner to provide Alzheimer’s clinical development samples (PDF)

Shionogi and Johnson & Johnson's Janssen are offering up access to data and samples from a discontinued Alzheimer’s disease clinical development program through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF). The information will be available though the ADDF Diagnostics Accelerator initiative, which funds R&D projects that identify and characterize biomarkers for Alzheimer’s.

Suggested Articles

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.